Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATASY Atlantia	$11.91 -0.4%	$11.91	$8.09 ▼ $12.61	$19.67B	0.9	38,992 shs	49,800 shs
DWHHF Deutsche Wohnen	$24.28	$24.28	$18.24 ▼ $28.65	N/A	0.86	2 shs	N/A
FRRVY Ferrovial	$31.00 +1.2%	$31.00	$21.90 ▼ $33.57	$22.55B	0.99	7,322 shs	39,400 shs
OMRNY Omron	$26.86 +1.9%	$26.78	$24.16 ▼ $47.75	$5.54B	1.04	47,798 shs	53,331 shs
SBMFF Sino Biopharmaceutical	$0.71	$0.60	$0.34 ▼ $0.77	$13.37B	0.6	2,191 shs	N/A

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATASY Atlantia	0.00%	0.00%	0.00%	0.00%	0.00%
DWHHF Deutsche Wohnen	0.00%	0.00%	0.00%	0.00%	+28.25%
FRRVY Ferrovial	0.00%	0.00%	0.00%	0.00%	0.00%
OMRNY Omron	0.00%	+4.49%	+1.63%	-6.39%	-28.14%
SBMFF Sino Biopharmaceutical	0.00%	+4.29%	+1.01%	+52.14%	+92.35%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ATASY Atlantia	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
DWHHF Deutsche Wohnen	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
FRRVY Ferrovial	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
OMRNY Omron	1.6006 of 5 stars	0.0	3.0	1.7	0.0	0.9	0.0	2.5
SBMFF Sino Biopharmaceutical	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATASY Atlantia	N/A	N/A	N/A
DWHHF Deutsche Wohnen	N/A	N/A	N/A
FRRVY Ferrovial	N/A	N/A	N/A
OMRNY Omron	N/A	N/A	N/A
SBMFF Sino Biopharmaceutical	N/A	N/A	N/A

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATASY Atlantia	$8.42B	2.34	$2.08 per share	5.73	$11.51 per share	1.03
DWHHF Deutsche Wohnen	$1.49B	N/A	N/A	N/A	$37.85 per share	N/A
FRRVY Ferrovial	$7.96B	2.83	$0.31 per share	99.44	$9.15 per share	3.39
OMRNY Omron	$5.26B	1.05	$1.59 per share	16.91	$29.90 per share	0.90
SBMFF Sino Biopharmaceutical	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATASY Atlantia	$740.62M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
DWHHF Deutsche Wohnen	-$638.98M	N/A	0.00	∞	N/A	N/A	N/A	N/A	8/8/2025 (Estimated)
FRRVY Ferrovial	$187.57M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
OMRNY Omron	$107.39M	$0.56	47.96	17.00	N/A	2.07%	1.75%	1.22%	8/1/2025 (Estimated)
SBMFF Sino Biopharmaceutical	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	8/11/2025 (Estimated)

Latest OMRNY, FRRVY, DWHHF, SBMFF, and ATASY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/8/2025	Q4 2025	OMRNY Omron	$0.4052	$0.30	-$0.1052	$0.30	$1.48 billion	$1.53 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATASY Atlantia	$0.26	2.18%	N/A	N/A	N/A
DWHHF Deutsche Wohnen	N/A	N/A	N/A	N/A	N/A
FRRVY Ferrovial	N/A	N/A	N/A	N/A	N/A
OMRNY Omron	$0.61	2.27%	N/A	108.93%	N/A
SBMFF Sino Biopharmaceutical	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATASY Atlantia	1.53	2.61	N/A
DWHHF Deutsche Wohnen	N/A	6.45	6.45
FRRVY Ferrovial	N/A	N/A	N/A
OMRNY Omron	0.13	2.31	1.57
SBMFF Sino Biopharmaceutical	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATASY Atlantia	N/A
DWHHF Deutsche Wohnen	N/A
FRRVY Ferrovial	N/A
OMRNY Omron	1.09%
SBMFF Sino Biopharmaceutical	N/A

Insider Ownership

Company	Insider Ownership
ATASY Atlantia	N/A
DWHHF Deutsche Wohnen	N/A
FRRVY Ferrovial	N/A
OMRNY Omron	N/A
SBMFF Sino Biopharmaceutical	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATASY Atlantia	29,151	1.65 billion	N/A	Not Optionable
DWHHF Deutsche Wohnen	4,942	N/A	N/A	Not Optionable
FRRVY Ferrovial	18,680	727.44 million	N/A	Not Optionable
OMRNY Omron	28,450	206.24 million	N/A	Not Optionable
SBMFF Sino Biopharmaceutical	25,806	18.79 billion	N/A	Not Optionable

OMRNY, FRRVY, DWHHF, SBMFF, and ATASY Headlines

Recent News About These Companies

Sino Biopharmaceutical’s New Breast Cancer Treatment Gains Regulatory Acceptance

July 10, 2025 | tipranks.com

Sino Biopharmaceutical (OTCMKTS:SBMFF) Sees Large Volume Increase - Time to Buy?

July 2, 2025 | marketbeat.com

Sino Biopharmaceutical Ltd (1177) - Investing.com UK

July 1, 2025 | uk.investing.com

Sino Biopharmaceutical’s LM-108 Gains Breakthrough Therapy Status in China

June 26, 2025 | tipranks.com

Sino Biopharmaceutical (OTCMKTS:SBMFF) Trading 8.7% Higher - Still a Buy?

June 23, 2025 | marketbeat.com

Sino Biopharmaceutical (OTCMKTS:SBMFF) Sees Large Decline in Short Interest

June 18, 2025 | marketbeat.com

Sino Biopharmaceutical (OTCMKTS:SBMFF) Trading Down 4.4% - Should You Sell?

June 17, 2025 | marketbeat.com

Sino Biopharmaceutical Secures Shareholder Approval for Key Resolutions at AGM

June 10, 2025 | tipranks.com

Sino Biopharmaceutical’s Phase III Study Shows Promising Results for NSCLC Treatment

June 3, 2025 | tipranks.com

SBMFF Sino Biopharmaceutical Limited

May 29, 2025 | seekingalpha.com

Sino Biopharmaceutical’s TQB2868 Shows Promise in Pancreatic Cancer Treatment

May 29, 2025 | tipranks.com

Sino Biopharmaceutical Unveils Promising Phase I Data for TQB2102 at ASCO 2025

May 27, 2025 | tipranks.com

Global First-in-Class AT2R Antagonist TRD205 Advances to Phase II: First Patient Dosed in Chronic Post-Surgical Neuropathic Pain Trial

May 6, 2025 | msn.com

U.S. FDA Approves China-Produced Cancer Drug

April 28, 2025 | forbes.com

Akeso, Sino Biopharm’s Anniko enters crowded PD-1 market with FDA approval in head and neck cancer subtype

April 25, 2025 | fiercepharma.comF

Sino Biopharmaceutical’s Penpulimab Injection Gains US FDA Approval

April 25, 2025 | tipranks.com

Sino Biopharmaceutical to Showcase 45 Research Results at 2025 ASCO Meeting

April 24, 2025 | tipranks.com

Sino Biopharmaceutical’s TQB3019 Approved for Clinical Trials

April 9, 2025 | tipranks.com

Sino Biopharmaceutical Receives Approval for Clinical Trial of New Cancer Drug

April 3, 2025 | tipranks.com

Sino Biopharmaceutical’s TQB6411 Clinical Trial Application Accepted

April 3, 2025 | tipranks.com

Sino Biopharmaceutical Reports Positive Phase III Results for Breast Cancer Treatment

March 24, 2025 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

OMRNY, FRRVY, DWHHF, SBMFF, and ATASY Company Descriptions

Atlantia OTCMKTS:ATASY

$11.91 -0.05 (-0.42%)

As of 12/21/2022

Atlantia SpA, through its subsidiaries, engages in the construction and operation of motorways, airports and transport infrastructure, parking areas, and intermodal systems worldwide. It operates and manages approximately 13,000 kilometers of toll motorways. The company manages, maintains, constructs, and widens related motorways operated under concession; and provides support for the Italian motorway operators. It also operates and expands Rome's Fiumicino and Ciampino airports; and operates the airports of Nice, Cannes-Mandelieu, and Saint-Tropez. In addition, the company engages in the design, project management, controlling, and maintenance of road and airport infrastructures; and operation of toll payment systems, as well as provides assistance and toll management services. Further, it operates free-flow tolling systems, traffic and transport management systems, and electronic payment systems. Additionally, the company offers insurance brokerage, as well as engineering services. Atlantia SpA was incorporated in 1950 and is headquartered in Rome, Italy.

Deutsche Wohnen OTCMKTS:DWHHF

$24.28 0.00 (0.00%)

As of 07/11/2025

Deutsche Wohnen SE develops and manages residential properties in Germany. The company operates through Rental, Value-add, Recurring Sales, Development, and Care segment. The Rental segment offers value-enhancing management to residential real estate portfolio. The Value- add segment engages in the core business of letting. This segment also includes multimedia services and the supply of energy. The Recurring Sales segment includes sales of individual condominiums and single-family homes. The Development segment includes project development to create new living space. The care segment includes all activities related to the management of care facilities and the leasing of care properties. Deutsche Wohnen SE was founded in 1924 and is headquartered in Berlin, Germany. Deutsche Wohnen SE operates as a subsidiary of Vonovia SE.

Ferrovial OTCMKTS:FRRVY

$31.00 +0.37 (+1.21%)

As of 08/3/2023

Ferrovial SE, together with its subsidiaries, develops transport infrastructure, mobility solutions, civil works, and buildings projects in Spain and internationally. The company designs and builds various public and private works; and develops, finances, and operates toll roads. Its construction activities include highways, tunnels, bridges, and airports; designs, constructs, operates and maintains potable water treatment plants, urban and industrial waste water treatment plants, and desalination plants. In addition, the company manufactures and markets asphalt and bitumen products; develops, operates, and manages airports; and promotes, constructs, and operates energy generation and transmission infrastructures. Further, it provides mobility services, include ZITY, an electric carsharing service application; invests in electric vehicle sector, including cars and associated charging infrastructures; and sells, rents, and maintains hydraulic equipment, jacks, and floating caisson equipment. The company was founded in 1952 and is based in Madrid, Spain.

Omron OTCMKTS:OMRNY

$26.86 +0.49 (+1.86%)

As of 07/11/2025 03:56 PM Eastern

OMRON Corporation engages in industrial automation, device and module solutions, social systems, and healthcare businesses worldwide. The Industrial Automation Business offers sensors, switches, safety and control components, relays, motion and drives, robotics, energy conservation, power supplies, and automation system products. It also offers environmental mobility, digital devices, food and commodity, logistic and warehouse automation, medical, robotic, panel, vision, software, and traceability related solutions. The Social Systems, Solutions and Service Business provides energy, public transport, traffic safety, network protection, payment, infrastructure monitoring, management service, and DX solutions, as well as offers remote surveillance/monitoring, automation/robotics, software development, engineering/maintenance, and other services. The Healthcare Business provides cardiovascular, respiratory care, pain management, remote patient monitoring, and other solutions. The Device and Module Solutions Business offers relays, switches, connectors, and sensors. OMRON Corporation was founded in 1933 and is headquartered in Kyoto, Japan.

Sino Biopharmaceutical OTCMKTS:SBMFF

$0.71 0.00 (0.00%)

As of 07/11/2025

Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company offers oncology medicines, including anlotinib hydrochloride capsules under Focus V brand, penpulimab injection under Annike brand, efbemalenograstin alfa injection under Yilishu brand, pomalidomide capsules under Anyue brand, bevacizumab injection under Anbeisi brand, rituximab injection under Delituo brand, and trastuzumab for injection under Saituo brand; liver disease medications, such as magnesium isoglycyrrhizinate injection under Tianqing Ganmei brand and entecavir dispersible tablets under Runzhong brand; and respiratory system medicines comprising budesonide suspension for inhalation under Tianqing suchang brand and colistimethate sodium for injection under Tianyun brand. It also provides surgery/analgesia medicines, including flurbiprofen cataplasms under the brand Zepolas, limaprost tablets under the brand Kailitong, and recombinant human coagulation factor VIII for injection under the brand Anhengji; cardio-cerebral vascular medicines, such as irbesartan and hydrochlorothiazide tablets under the brand Yilunping and beraprost sodium tablets under the brand Kaina; and biosimilar medicines comprising adalimumab solution for injection under the brand Taibowei. In addition, the company develops oncology drugs, include benmelstobart, D-1553, TQ-B3139, and TQ-B3101; liver disease drugs, such as Lanifibranor and TQA2225/AP025; respiratory system drugs comprising TDI01, TQC2731, TCR1672, TQC3721, and TQH2722; and surgery/analgesia drugs, including PL-5, an antimicrobial peptide. Further, it is involved in the long-term investments; and healthcare and hospital business. The company was incorporated in 2000 and is headquartered in Wan Chai, Hong Kong.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time